

# Financial Tear Sheet

## Corporate Profile

Fibrocell is an autologous cell and gene therapy company translating personalized biologics into medical breakthroughs. Fibrocell's most advanced product candidate, azficel-T, uses its proprietary autologous fibroblast technology and is in a Phase II clinical trial for the treatment of vocal fold scarring resulting in chronic or severe dysphonia. In collaboration with Intrexon Corporation (NYSE:XON), a leader in synthetic biology, Fibrocell is also developing gene therapies for skin and joint diseases using genetically-modified autologous fibroblasts. Fibrocell is in preclinical development of FCX-007, its orphan gene-therapy product candidate, for the treatment of recessive dystrophic epidermolysis bullosa (RDEB). Fibrocell is also in preclinical development of FCX-013, its gene-therapy product candidate, for the treatment of linear scleroderma. In addition, Fibrocell and Intrexon will be commencing preclinical development of a gene therapy for the treatment of chronic inflammatory and degenerative diseases of the joint, including arthritis and related conditions

## Stock Information

### FCSC (Common Stock)

<b>Exchange</b>	NASDAQ CM (US Dollar)
<b>Price</b>	<b>\$1.45</b>
<b>Change (%)</b>	<b>▲ 0.07 (5.07%)</b>
<b>Volume</b>	68,138
<b>52 Week Low</b>	\$1.36
<b>Market Cap</b>	\$21,343,981
<b>Rolling EPS</b>	-1.81
<b>PE Ratio</b>	N/A
<b>Shares Outstanding</b>	14,719,987

Data as of 11/24/17 1:00 p.m. ET



## Recent Headlines & Events

11/13/17 - 8:00 a.m.  
Fibrocell Reports Third Quarter 2017 Financial Results and Recent Highlights

11/06/17 - 8:01 a.m.  
Fibrocell to Host Conference Call and Webcast on Monday, November 13, 2017 to Discuss Third

There are currently no events scheduled.

Quarter 2017 Financial Results and Recent  
Operational Highlights

10/02/17 - 4:30 p.m.

Fibrocell to Present at 2017 Cell & Gene Meeting on  
the Mesa

**SEC Filings**

Filing Date	Form
11/17/17	FWP
11/17/17	S-1/A
11/15/17	8-K
11/13/17	10-Q

**Corporate Governance**

Douglas J. Swirsky	Chairman of the Board
Julian P. Kirk	Director
Marc B. Mazur	Director
John Maslowski	Director
Kelvin D. Moore	Director
Marcus E. Smith	Director
Christine St.Clare	Director

**Ownership Summary**

Shareholders				
	Holders	Value (\$MM)	% O/S	Shares
Institution	41	24.87	55.3	8,133,116
Mutual Fund	15	2.68	6.3	924,158
Director and Officer	1	.25	0.7	105,600

\*Insider values reflect direct beneficial ownership.

**Top Holders**

	Shares Held	% O/S	Share Change	Filing Date
Third Security, LLC	5,540,140	37.6	0	09/30/17
MSD Partners, L.P.	692,960	4.7	0	09/30/17
Fidelity Management & Research Company	587,414	4.0	-262,800	09/30/17
The Vanguard Group, Inc.	328,576	2.2	-18,000	09/30/17
Pura Vida Investments, LLC	297,000	2.0	297,000	09/30/17
Renaissance Technologies LLC	118,764	0.8	10,500	09/30/17
Morgan Stanley Wealth Management	82,602	0.6	47,866	09/30/17
Creative Planning, Inc.	61,090	0.4	0	09/30/17
Geode Capital Management, L.L.C.	58,710	0.4	0	09/30/17
Parametric Portfolio Associates LLC	48,259	0.3	0	09/30/17

Data provided by Nasdaq. Minimum 15 minutes delayed.